Loading...

Cardiol Therapeutics Inc.

CRDL.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
CA$1.62
CA$0.00(0.00%)

Cardiol Therapeutics Inc. (CRDL.TO) Financial Performance & Income Statement Overview

Explore the financials of Cardiol Therapeutics Inc. (CRDL.TO), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
0.00%
Operating Income Growth
-35.22%
35.22%
Net Income Growth
-30.39%
30.39%
Operating Cash Flow Growth
-99425.13%
99425.13%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-210.17%
210.17%
ROIC
-147.76%
147.76%

Cardiol Therapeutics Inc. (CRDL.TO) Income Statement & Financial Overview

Explore comprehensive income reports for Cardiol Therapeutics Inc. CRDL.TO, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$0.00$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$0.00$61908.00
Gross Profit$0.00$0.00$0.00-$61908.00
Gross Profit Ratio$0.00$0.00$0.00$0.00
R&D Expenses$3.76M$4.23M$3.75M$2.71M
SG&A Expenses$4.65M$5.76M$10.39M$4.97M
Operating Expenses$8.43M$9.99M$14.14M$7.68M
Total Costs & Expenses$8.43M$9.99M$14.14M$7.74M
Interest Income$248269.00$306775.00$201864.00$307409.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$24986.00$48493.00$201090.00$61908.00
EBITDA-$8.40M-$9.94M-$13.94M-$7.68M
EBITDA Ratio$0.00$0.00$0.00$0.00
Operating Income-$8.43M-$9.99M$0.00-$7.74M
Operating Income Ratio$0.00$0.00$0.00$0.00
Other Income/Expenses (Net)$141410.00$1.81M$1.41M$1.15M
Income Before Tax-$8.29M-$8.18M-$12.73M-$6.59M
Income Before Tax Ratio$0.00$0.00$0.00$0.00
Income Tax Expense$0.00$0.00$0.00$0.00
Net Income-$8.29M-$8.18M-$12.73M-$6.59M
Net Income Ratio$0.00$0.00$0.00$0.00
EPS-$0.10-$0.10-$0.18-$0.10
Diluted EPS-$0.10-$0.10-$0.18-$0.10
Weighted Avg Shares Outstanding$82.61M$81.78M$69.84M$68.75M
Weighted Avg Shares Outstanding (Diluted)$82.61M$81.78M$69.84M$68.75M

Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$8.43M in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$8.40M. Net income dropped to -$8.29M, keeping EPS at -$0.10. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;